| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
Not applicable; (5)6-Carboxytetramethylrhodamine is a protein/peptide labeling dye.
|
|---|---|
| ln Vitro |
Not applicable as (5)6-CTM is a protein labeling dye.
|
| ln Vivo |
Not applicable as (5)6-CTM is a protein labeling dye.
|
| Enzyme Assay |
Standard protein labeling protocol: Dissolve (5)6-Carboxytetramethylrhodamine (10 mg) in DMSO to prepare a 10 mM stock. For labeling, dissolve target protein (e.g., antibody, BSA, streptavidin) in 0.1 M NaHCO3 buffer (pH 8.5). Activate the dye by adding EDC (20 mM final) and NHS (50 mM final) and incubate for 15 min at room temperature. Add the activated dye to the protein solution at 10-20 molar excess. Incubate for 2 hours at room temperature with gentle agitation. Remove unbound dye by size-exclusion chromatography or dialysis. Measure degree of labeling by absorbance at 555 nm and 280 nm.
|
| Cell Assay |
Not applicable for direct in vivo use of the unconjugated dye; however, the dye-protein conjugate (e.g., (5)6-CTM-labeled antibody) can be used for in vivo imaging. Administer the labeled antibody (50-200 ug per mouse) via tail vein injection. Allow 24-48 hours for distribution and tumor targeting. Anesthetize mice and perform whole-body fluorescence imaging using an IVIS system with 530/550 nm excitation and 575/620 nm emission filters. After imaging, euthanize mice, harvest major organs and tumors, and image ex vivo.
|
| ADME/Pharmacokinetics |
(5)6-Carboxytetramethylrhodamine has a molecular weight of 431.46 g/mol. As a small-molecule dye, the unconjugated form is rapidly cleared from circulation (t1/2 ~0.5-1 h) via renal and hepatobiliary excretion. The dye is moderately soluble in aqueous buffers (requires DMSO for stock solution). When conjugated to proteins or nanoparticles, the pharmacokinetic behavior is dictated by the carrier molecule; for example, antibody conjugates have long half-lives (t1/2 of days) whereas peptide conjugates clear more rapidly.
|
| Toxicity/Toxicokinetics |
The unconjugated dye (5)6-CTM is not intended for in vivo use due to rapid clearance and potential non-specific binding. For dye-labeled conjugates, the toxicity profile is primarily driven by the carrier molecule (antibody, peptide, nanoparticle). No significant toxicity associated with the tetramethylrhodamine fluorophore itself has been reported at standard imaging doses. Standard chemical safety precautions should be followed.
|
| References | |
| Additional Infomation |
(5)6-Carboxytetramethylrhodamine is a workhorse fluorophore in molecular biology, widely used in fluorescence microscopy, flow cytometry, FRET (Förster resonance energy transfer) assays, and as a standard for instrument calibration. It is commonly used as the acceptor fluorophore in fluorescein (FITC)-TAMRA FRET pairs. The dye is available as a mixed isomer (5- and 6- carboxy) or as the pure 5- or 6-isomer. It is not approved for clinical diagnostic or therapeutic use and is strictly for research applications.
|
| Molecular Formula |
C25H23N2O5+
|
|---|---|
| Molecular Weight |
431.46
|
| Exact Mass |
862.321
|
| CAS # |
117557-83-2
|
| PubChem CID |
168476192
|
| Appearance |
Gray to dark gray solid powder
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
12
|
| Rotatable Bond Count |
8
|
| Heavy Atom Count |
64
|
| Complexity |
1760
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CN(C)C1=CC2=C(C=C1)C(=C3C=CC(=[N+](C)C)C=C3O2)C4=C(C=C(C=C4)C(=O)O)C(=O)O.CN(C)C1=CC2=C(C=C1)C(=C3C=CC(=[N+](C)C)C=C3O2)C4=C(C=CC(=C4)C(=O)O)C(=O)O
|
| InChi Key |
PYOXZPUMKLJOGA-UHFFFAOYSA-P
|
| InChi Code |
InChI=1S/2C25H22N2O5/c1-26(2)15-6-9-18-21(12-15)32-22-13-16(27(3)4)7-10-19(22)23(18)20-11-14(24(28)29)5-8-17(20)25(30)31;1-26(2)15-6-9-18-21(12-15)32-22-13-16(27(3)4)7-10-19(22)23(18)17-8-5-14(24(28)29)11-20(17)25(30)31/h2*5-13H,1-4H3,(H-,28,29,30,31)/p+2
|
| Chemical Name |
[9-(2,4-dicarboxyphenyl)-6-(dimethylamino)xanthen-3-ylidene]-dimethylazanium;[9-(2,5-dicarboxyphenyl)-6-(dimethylamino)xanthen-3-ylidene]-dimethylazanium
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 20 mg/mL (46.35 mM)
Methanol: 5 mg/mL (11.59 mM) |
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.3177 mL | 11.5886 mL | 23.1771 mL | |
| 5 mM | 0.4635 mL | 2.3177 mL | 4.6354 mL | |
| 10 mM | 0.2318 mL | 1.1589 mL | 2.3177 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
